| 发明名称 | Levothyroxine formulations | ||
| 摘要 | A levothyroxine composition includes levothyroxine sodium and mannitol. The composition is a solid. The composition may include from 100 to 500 micrograms levothyroxine sodium and from 1 to 5 milligrams mannitol. The composition may include from 100 to 200 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 40:1. The composition may include about 500 micrograms levothyroxine sodium, and the mass ratio of mannitol to levothyroxine sodium in the composition may be at most 10:1. | ||
| 申请公布号 | US9006289(B2) | 申请公布日期 | 2015.04.14 |
| 申请号 | US201213597884 | 申请日期 | 2012.08.29 |
| 申请人 | Fresenius Kabi USA, LLC | 发明人 | Jiang Zhi-Qiang;Usayapant Arunya;Monen George |
| 分类号 | A61K31/198;A61K47/26;A61K9/00;A61K9/19 | 主分类号 | A61K31/198 |
| 代理机构 | Blanchard & Associates | 代理人 | Blanchard & Associates |
| 主权项 | 1. A composition, comprising: about 100 or about 200 micrograms of levothyroxine sodium; a phosphate buffer; and from 2 to 4 milligrams of mannitol, where the composition is a lyophilized solid. | ||
| 地址 | Lake Zurich IL US | ||